Skip to main content
49 search results for:

Chronic myeloid leukemia 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 31-01-2022 | Chronic myeloid leukemia | Adis Journal Club | Article
    Advances in Therapy

    Chronic Myeloid Leukemia Data at ASH 2021: A Podcast on Patient Unmet Needs and Later-Line Treatment Developments

  2. 02-02-2018 | Chronic myeloid leukemia | Editorial | Article

    Discontinuing tyrosine kinase inhibitors in chronic myeloid leukemia

    Tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) can result in prolonged and deep responses in many patients. In such cases, can TKIs be safely discontinued to avoid adverse side effects and costs? Etab Atallah (Medical College of Wisconsin, USA) discusses the current issues surrounding TKI discontinuation in CML.

  3. 02-02-2018 | Chronic myeloid leukemia | Highlight | Teaser
    Expert opinion

    Discontinuing tyrosine kinase inhibitors in chronic myeloid leukemia

    Tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) can result in prolonged and deep responses in many patients. In such cases, can TKIs be safely discontinued to avoid adverse side effects and costs? Etab Atallah (Medical College of Wisconsin, USA) discusses the current issues surrounding TKI discontinuation in CML.

  4. 10-09-2018 | Chronic myeloid leukemia | Article

    Cardiovascular events in chronic myeloid leukemia clinical trials. Is it time to reassess and report the events according to cardiology guidelines?

    Aghel N, Delgado DH, Lipton JH. Leukemia  2018. doi:10.1038/s41375-018-0247-1.

  5. 18-08-2016 | Chronic myeloid leukemia | Book chapter | Article

    Epidemiology of chronic myeloid leukemia

    Höglund M, Sandin F, & Simonsson B. In:  Chronic Myeloid Leukemia . Edited by Hehlmann R. Springer International Publishing, 2016. doi:10.1007/978-3-319-33198-0_7

  6. 12-09-2017 | Chronic myeloid leukemia | Article

    Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

    Based on an analysis of the randomized chronic myeloid leukemia study-IV trial, Hehlmann et al. show the high survival probabilities that can be achieved with imatinib-based monotherapy (400 mg/day). Leukemia 2017. doi:10.1038/leu.2017.253

  7. 03-06-2016 | Chronic myeloid leukemia | Article

    European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

    This article provides the European LeukemiaNet recommendations for managing and avoiding adverse events in patients receiving tyrosine kinase inhibitors for chronic myeloid leukemia. Leukemia  2016; 30: 1648–1671. doi:10.1038/leu.2016.104

  8. 07-03-2018 | Chronic myeloid leukemia | News | Article
    News in brief

    Dasatinib confirmed as pediatric chronic phase CML option

    The tyrosine kinase inhibitor dasatinib is effective and well tolerated as a first- or second-line therapy for children with chronic myeloid leukemia in the chronic phase, research confirms.

  9. 29-08-2017 | Chronic myeloid leukemia | News | Article
    News in brief

    First-line imatinib at 10 years: CML patients achieve ‘close to normal life expectancy’

    Findings from the chronic myeloid leukemia IV study suggest that patients in the chronic phase who respond to imatinib have a high likelihood of survival at 10 years.

  10. 11-01-2019 | Tyrosine kinase inhibitors | News | Article

    Concomitant TKI–PPI use may adversely affect cancer patient survival

    The analysis included patients aged at least 65 years who received TKI treatment for lung cancer, renal cell carcinoma (RCC), chronic myeloid leukemia (CML), liver cancer, or pancreatic cancer between 2007 and 2012.

  11. 03-05-2019 | EMA | News | Article
    approvalsWatch

    Biosimilar pegfilgrastim receives EMA go-ahead, generic cabazitaxel does not

    However, this positive opinion does not include use in patients with chronic myeloid leukemia or myelodysplastic syndromes. --- The Committee adopted a negative opinion for marketing authorization for the hybrid medicine Cabazitaxel Teva (Teva Europe BV, Amsterdam, the Netherlands), alongside prednisone or prednisolone, in patients with metastatic castration-resistant prostate cancer, who have previously been treated with docetaxel.

  12. 22-06-2017 | Chronic myeloid leukemia | News | Article
    ASCO 2017

    Frontline bosutinib ‘an option’ for newly diagnosed CP CML

    Study findings suggest that bosutinib could be considered as an alternative to imatinib for first-line tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase.

  13. 31-07-2017 | Leukemia | Article

    Targeted next-generation sequencing identifies clinically relevant mutations in patients with chronic neutrophilic leukemia at diagnosis and blast crisis

    Next-generation sequencing is shown to be able to identify clinically relevant myeloid malignancy-associated mutations when applied to a case series of patients with chronic neutrophilic leukemia. Langabeer SE et al. Clin Transl Oncol 2017. doi:10.1007/s12094-017-1722-2

  14. 26-07-2017 | Teaser

    Multiple myeloma minimal residual disease

    This chapter reviews the different levels of remission used to define depth of response in myeloma and their clinical significance, as well as the prognostic value and unique characteristics of minimal residual disease detection. Summary points Assessment of minimal residual disease (MRD) is becoming standard diagnostic care for potentially curable neoplasms such as some acute leukemias as well as chronic myeloid and lymphocytic leukemia. Multiple myeloma (MM) remains an incurable disease and no clinical trial has randomized MM patients according to their MRD status in order to investigate the role of MRD to individualize therapy. The experience of several cooperative groups using different MRD techniques has indicated that persistence of MRD is always an adverse prognostic feature. It is thus recommended that it would be safer to take clinical decisions based on MRD-positivity rather than on MRD-negativity, since the patchy pattern of bone marrow (BM) infiltration typically observed in MM leads to a degree of uncertainty regarding MRD-negative results: does this guarantee absence of tumor cells or is it the result of a non-representative BM sample due to patchy tumor infiltration? Many studies have shown the value of MRD to evaluate the efficacy of specific treatment phases and therefore to support potential treatment decisions. Several groups have confirmed the added value of MRD in MM, and the time has come to establish the role of baseline risk factors plus MRD monitoring for tailored therapy. This requires the introduction of standardized, highly sensitive, cost-effective, and broadly available MRD techniques in clinical trials. The choice of MRD technology for monitoring will depend on how individual centers’ priorities adjust to the specific advantages that each tool has to offer. Paiva B, García-Sanz R, & San Miguel JF. In:  Plasma Cell Dyscrasias . Edited by Roccaro AM & Ghobrial IM. Springer International Publishing, 2016. doi:10.1007/978-3-319-40320-5_7

  15. 19-04-2017 | Chronic myeloid leukemia | News | Article

    First-line generic imatinib offers ‘suboptimal efficacy’

    For patients undergoing front-line treatment for chronic myeloid leukemia, generic treatment may be less effective than the branded agent, researchers suggest, but treatment efficacy is maintained in patients who switch from a branded to a generic formulation.

  16. 12-04-2017 | Chronic myeloid leukemia | News | Article

    Molecular response depth may predict imatinib resistance risk

    Study findings suggest that the depth of molecular response to imatinib achieved by a patient with chronic myeloid leukemia may influence the relationship between a fluctuating response to treatment and the likelihood of developing resistance to the tyrosine kinase inhibitor.

  17. 29-03-2017 | Chronic myeloid leukemia | News | Article

    CML treatment-free remission possible with nilotinib

    The ENESTfreedom study of patients who stopped first-line nilotinib after achieving a sustained deep molecular response has shown that around half of chronic myeloid leukemia patients continue in remission.

  18. 29-03-2017 | Chronic myeloid leukemia | News | Article

    CML progression, outcome linked to smoking

    Findings from the German CML Study IV indicate that patients with chronic myeloid leukemia are more likely to experience disease progression and have lower overall survival if they smoke.

  19. 17-03-2017 | Chronic myeloid leukemia | News | Article

    Imatinib efficacy for CML sustained over time

    Overall survival among patients with chronic myeloid leukemia remains high after nearly 11 years of treatment with imatinib, analysis of phase III study data shows.

  20. 09-04-2018 | FDA | News | Article
    approvalsWatch

    FDA announces further approvals for nilotinib, blinatumomab

    Click through for more information about these leukemia decisions

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.